The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesWB: Use at a concentration of 1 µg/ml. Detects a band of approximately 75 kDa (predicted molecular weight: 61 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionRegulates cell cycle checkpoints and apoptosis in response to DNA damage, particularly to DNA double-strand breaks. Inhibits CDC25C phosphatase by phosphorylation on 'Ser-216', preventing the entry into mitosis. May also play a role in meiosis. Regulates the TP53 tumor suppressor through phosphorylation at 'Thr-18' and 'Ser-20'.
Tissue specificityHigh expression is found in testis, spleen, colon and peripheral blood leukocytes. Low expression is found in other tissues.
Involvement in diseaseDefects in CHEK2 are associated with Li-Fraumeni syndrome 2 (LFS2) [MIM:609265]; a highly penetrant familial cancer phenotype usually associated with inherited mutations in p53/TP53. Defects in CHEK2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Defects in CHEK2 are found in some patients with osteogenic sarcoma (OSRC) [MIM:259500].
Sequence similaritiesBelongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family. CHK2 subfamily. Contains 1 FHA domain. Contains 1 protein kinase domain.
Post-translational modificationsPhosphorylated by PLK4.
Cellular localizationNucleus; Nucleus. Isoform 10 is present throughout the cell and Nucleus > PML body. Nucleus > nucleoplasm. Recruited into PML bodies together with TP53.
Western blot - Chk2 (phospho T26) antibody (ab26338)
All lanes : Anti-Chk2 (phospho T26) antibody (ab26338) at 1 µg/ml
Lane 1 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg Lane 2 : Gamma-Irradiated HeLa Lysate - 4 hour exposure at 20 µg Lane 3 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg with Human Chk2 (phospho T26) peptide (ab27902) at 1 µg/ml Lane 4 : Gamma-Irradiated HeLa Lysate - 4 hour exposure at 20 µg with Human Chk2 (phospho T26) peptide (ab27902) at 1 µg/ml Lane 5 : HeLa (Human epithelial carcinoma cell line) Whole Cell Lysate at 10 µg with Human Chk2 peptide (ab37237) at 1 µg/ml Lane 6 : Gamma-Irradiated HeLa Lysate - 4 hour exposure at 20 µg with Human Chk2 peptide (ab37237) at 1 µg/ml
Immunocytochemistry/ Immunofluorescence - Chk2 (phospho T26) antibody (ab26338)This image is courtesy of an Abreview submitted by Dr Kirk McManus
ab26338 (1/500) staining Chk2 (phospho T26) in HeLa cells (green). Cells were fixed with paraformaldehyde, permeabilised with 0.5% Triton X100/PBS and counterstained with DAPI (blue) in order to highlight the nucleus. The colocalisation of Chk2-pT26 and g-H2AX following bleomycin treatment (induces DNA strand breaks) was confirmed using an anti-gamma H2AX antibody (red). Please refer to abreview for further experimental details.
References for Anti-Chk2 (phospho T26) antibody (ab26338)
This product has been referenced in:
Harper LJ et al. Normal and malignant epithelial cells with stem-like properties have an extended G2 cell cycle phase that is associated with apoptotic resistance. BMC Cancer10:166 (2010).
Read more (PubMed: 20426848) »